Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678924 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT01678924: Clinical Trial Phase 2 study, sponsored by Allergan.
NCT01678924 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 280 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01678924, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).
Primary Outcome
The average pain intensity score at each week was the mean of the daily average pain intensity scores reported in the patient's eDiary during each 7-day period, starting with the day of study treatment injection. Patients used the 11-point Likert scale, with anchors at 0 = "no pain" and 10 = "pain as bad as you can imagine" Baseline was defined as the mean of the daily average pain intensity scores reported during the baseline period for the 7 days immediately prior to the treatment.
Interventions
- DRUG AGN-214868
- DRUG AGN-214868 Placebo (Vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT01678924 stopped before completion
NCT01678924 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which AGN-214868 is the first listed.
NCT01678924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01678924 about?
NCT01678924 is a clinical study titled "A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia". This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).
What is the current status of trial NCT01678924?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2013-01. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01678924?
The interventions under investigation include: AGN-214868 (DRUG), AGN-214868 Placebo (Vehicle) (DRUG).
Who is sponsoring clinical trial NCT01678924?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01678924's enrollment target sits among peer trials
280 196th of 2000 higher than 1,800 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia